Evening of 21st March 2018

Transgene develops innovative immunotherapies against cancers and infectious diseases. Our approach aims to stimulate the immune responses of patients to attack diseased cells on multiple fronts. Five products are in Phase 1 to 3 of clinical trials. With our Invir.IOTM platform, we are designing a new generation of multifunctional oncolytic viruses. Meet our management to discuss our achievements of 2017 and prospects of 2018/2019.

Wednesday, March 21, 2018

NORMANDY HOTEL, 7 rue de l’Echelle, 75001 Paris

7.15 pm OPENING

7.30 pm CONFERENCE TRANSGENE – Lounge Il Palazzo

Philippe ARCHINARD, CEO
Jean-Philippe DEL, VP Finance

– Our technology
– Our strategy
– Back on 2017 (launch of clinical trials and collaboration agreements)
– Presentation of our portfolio of products
– Key elements of the 2017 financial results
– Invir.IO, a new generation of oncolytic viruses
– Major meetings and catalysts of 2018

8.45 – 10.30 pm COCKTAIL
Discussions with management and networking